Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. Analyses from KEYTRUDA Plus LENVIMA Trials to…
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by…
Dateline City: KENILWORTH, N.J. KEYNOTE-204 is the First Positive Phase 3 Trial of an Anti-PD-1…
Dateline City: KENILWORTH, N.J. First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and…
Dateline City: KENILWORTH, N.J. Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab…
Dateline City: KENILWORTH, N.J. ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA®(pembrolizumab) in…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent…
Dateline City: KENILWORTH, N.J. First Medicine Approved to Treat This Rare and Debilitating Condition KENILWORTH,…
Dateline City: KENILWORTH, N.J. Supplemental Biologics License Application (sBLA) Accepted for KEYTRUDA Monotherapy in Patients…
Dateline City: KENILWORTH, N.J. The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival…
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented at…
Dateline City: KENILWORTH, N.J. Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in…
Dateline City: KENILWORTH, N.J. KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Certain Patients With…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. LYNPARZA Reduced the Risk of Disease Progression or Death by 47%…
Dateline City: KENILWORTH, N.J. KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H)…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States…
Dateline City: KENILWORTH, N.J. New Findings from Phase 3 KEYNOTE-042 Study Were Presented Today at…
Dateline City: KENILWORTH, N.J. & BURLINGTON, Mass. Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion…
Dateline City: KENILWORTH, N.J. AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or…
Dateline City: KENILWORTH, N.J. Application Based on Results from Phase 2 KEYNOTE-057 Trial, to be…
Dateline City: KENILWORTH, N.J. Third Approval for KEYTRUDA in First-Line NSCLC in China in Less…
Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the…